An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
Someone who tried semaglutide (the drug in Ozempic and Wegovy) says it worked really well for them. They started in early 2022 and lost about 80 pounds by the end of 2023. They describe it as easy: no constant hunger, mostly wanting vegetables and yogurt, and not thinking about food much. Then the cost went up—twice—and they couldn’t afford to keep taking it during a period of other life stress. Semaglutide is a medicine that copies a natural hormone made in the gut that helps control appetite and digestion. In plain terms, it tells your brain “you’re full” and it slows how fast the stomach empties so you feel satisfied longer. Doctors prescribe it for type 2 diabetes and, at higher doses, for chronic weight management. It’s given as a once-weekly injection and has become well-known because many people have seen big weight loss on it. What this short first-person report shows is an individual success story, not a controlled study. The person reported steady, substantial weight loss over nearly two years and a change in food preferences, which matches what clinical trials and many other users have reported. But this is a single anecdote. It doesn’t tell us about how typical that result is, how people fared long term after stopping, or whether there were other health checks or lifestyle changes involved. Why it matters is straightforward: semaglutide can be a powerful tool for weight loss for some people, and that can change daily life and health markers. If you’re someone struggling with appetite and weight, or a clinician thinking about treatment options, stories like this explain why demand has surged. It also highlights the practical reality that cost and access can derail even successful treatment plans—so affordability, insurance coverage, and supply are important issues. There are important caveats. Semaglutide can cause side effects like nausea, diarrhea, and constipation, and in rare cases more serious problems. It’s a prescription drug, so people should only use it under medical supervision. We don’t know from this story whether the person had other medical conditions, whether their doctor monitored them, or what happened after they stopped taking it because of price. Also, long-term effects and what happens when people discontinue treatment are still being studied. Bottom line: Semaglutide helped this person lose a lot of weight and curb hunger, but cost and access stopped the treatment—one powerful example of both the drug’s potential and the practical limits people face.
Source: r/Semaglutide